SE453569B - Gammabutyrobetain till anvendning for behandling av patienter som lider av l-karnitinbristsyndrom - Google Patents

Gammabutyrobetain till anvendning for behandling av patienter som lider av l-karnitinbristsyndrom

Info

Publication number
SE453569B
SE453569B SE8200007A SE8200007A SE453569B SE 453569 B SE453569 B SE 453569B SE 8200007 A SE8200007 A SE 8200007A SE 8200007 A SE8200007 A SE 8200007A SE 453569 B SE453569 B SE 453569B
Authority
SE
Sweden
Prior art keywords
carnitine
butyrobetaine
gamma
treatment
patients suffering
Prior art date
Application number
SE8200007A
Other languages
English (en)
Swedish (sv)
Other versions
SE8200007L (sv
Inventor
C Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SE8200007L publication Critical patent/SE8200007L/
Publication of SE453569B publication Critical patent/SE453569B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8200007A 1981-01-06 1982-01-04 Gammabutyrobetain till anvendning for behandling av patienter som lider av l-karnitinbristsyndrom SE453569B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT47518/81A IT1198434B (it) 1981-01-06 1981-01-06 Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina

Publications (2)

Publication Number Publication Date
SE8200007L SE8200007L (sv) 1982-07-07
SE453569B true SE453569B (sv) 1988-02-15

Family

ID=11260827

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8200007A SE453569B (sv) 1981-01-06 1982-01-04 Gammabutyrobetain till anvendning for behandling av patienter som lider av l-karnitinbristsyndrom

Country Status (15)

Country Link
US (1) US4382092A (fr)
JP (1) JPS57136516A (fr)
AU (1) AU548787B2 (fr)
BE (1) BE891639A (fr)
CH (1) CH649218A5 (fr)
DE (1) DE3200016A1 (fr)
FR (1) FR2497510B1 (fr)
GB (1) GB2091101B (fr)
GR (1) GR75132B (fr)
IE (1) IE52404B1 (fr)
IL (1) IL64632A0 (fr)
IT (1) IT1198434B (fr)
LU (1) LU83869A1 (fr)
NL (1) NL8200022A (fr)
SE (1) SE453569B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1190280B (it) * 1986-04-24 1988-02-16 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di gamma-butirrobetaina
US5030458A (en) * 1989-11-27 1991-07-09 Shug Austin L Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats
IT1219448B (it) * 1988-02-12 1990-05-18 Sigma Tau Ind Farmaceuti Alimento per animali domestici carnivori, in particolare per cani integrato con l-carnitina
US5240961A (en) * 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
US20030170290A1 (en) * 1993-06-16 2003-09-11 Shug Austin L. Delayed release carnitine
JP2553013B2 (ja) * 1993-07-19 1996-11-13 ヤマハ発動機株式会社 燃料噴射式エンジンの吸気装置
US5569457A (en) * 1994-11-18 1996-10-29 Shug; Austin L. Method of stimulating antibody formation
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11727B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
LV11728B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
AUPO821097A0 (en) * 1997-07-25 1997-08-14 Cultor Ltd. A prophylactic
KR100411275B1 (ko) * 1999-09-15 2003-12-18 주식회사 포스코 언로더 코일 적치위치 제어장치
DE19956772A1 (de) * 1999-11-25 2001-06-07 Basf Ag Verwendung von y-Butyrobetain Salzen zur Herstellung von Zubereitungen für die menschliche und tierische Ernährung
US6476010B2 (en) 2000-03-10 2002-11-05 Hill's Pet Nutrition Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals
LV12979B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism

Also Published As

Publication number Publication date
DE3200016C2 (fr) 1992-12-03
IE813099L (en) 1982-07-06
CH649218A5 (it) 1985-05-15
AU7908781A (en) 1982-07-15
LU83869A1 (fr) 1982-05-07
NL8200022A (nl) 1982-08-02
DE3200016A1 (de) 1982-08-12
JPH0424325B2 (fr) 1992-04-24
IT8147518A0 (it) 1981-01-06
GR75132B (fr) 1984-07-13
GB2091101B (en) 1985-02-20
IL64632A0 (en) 1982-03-31
AU548787B2 (en) 1986-01-02
BE891639A (fr) 1982-04-16
FR2497510B1 (fr) 1986-04-25
JPS57136516A (en) 1982-08-23
IT1198434B (it) 1988-12-21
IE52404B1 (en) 1987-10-14
GB2091101A (en) 1982-07-28
SE8200007L (sv) 1982-07-07
FR2497510A1 (fr) 1982-07-09
US4382092A (en) 1983-05-03

Similar Documents

Publication Publication Date Title
SE453569B (sv) Gammabutyrobetain till anvendning for behandling av patienter som lider av l-karnitinbristsyndrom
US10111849B2 (en) Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US9138420B2 (en) Compositions and methods for producing elevated and sustained ketosis
JP5701245B2 (ja) アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用
JP2001517085A (ja) 激しい運動に対する骨格筋の適用を容易するため、および無力症者における疲労に対処するための栄養補助剤
JP2001510799A (ja) 必須脂肪酸および生物活性ジスルフィドを含む治療用および食餌療法用組成物
CN112292122A (zh) 使用烟酰胺腺嘌呤二核苷酸(nad+)前体和至少一种酮或酮前体的组合物和方法
US20230255917A1 (en) Methods of treating amyotrophic lateral sclerosis
EP0844875A2 (fr) Utilisation des aminoacides de base et de leurs derives pour abaisser les taux de ceramide
US20080269307A1 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
US20230364042A1 (en) Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses
US20190119705A1 (en) Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof
CN113230273A (zh) 一种含有胆碱、b族维生素、叶酸、锌的防治高同型半胱氨酸血症的复方制剂
EP0590355B1 (fr) Utilisation de L-carnitine et d'acyl L-carnitines pour le traitement de patients souffrants de syndromes liés au SIDA et de patients VIH-séropositifs asymptomatiques
EP4331583A1 (fr) Agent augmentant la carnitine sanguine
JPH07233070A (ja) 疲労改善剤
EP3804705B1 (fr) Composition pharmaceutique destinée à prévenir le diabète et utilisation correspondante
WO2020049549A1 (fr) Formulation contenant du magnésium et ses utilisations
US11510889B2 (en) Methods for inhibiting the progression of neurodegenerative diseases
US20240115535A1 (en) Methods for Inhibiting the Progression of Neurodegenerative Diseases
WO2008021996A2 (fr) Complément nutritionnel fournissant une énergie et une endurance accrues
US7919533B2 (en) Diiodothyroacetic acid and method of use
WO2019109050A1 (fr) Prévention et traitement de l'atrophie musculaire au moyen d'une apport complémentaire en cétones

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8200007-6

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8200007-6

Format of ref document f/p: F